Latest Breaking News On - Phase 3 cares 310 trial - Page 1 : comparemela.com

Amit Mahipal, MD, discusses clinical outcomes with camrelizumab plus rivoceranib as first-line treatment in unresectable HCC, based on data from the randomized, open-label, international phase 3 CARES-310 trial.

United statesAmit mahipalGi oncology programUniversity hospitals in rochesterCase western reserve universityUniversity hospitalsUnresectable hepatocellular carcinoma hccPhase 3 cares 310 trial